Overview

Study of the Safety and Leukostimulatory Activity of the Preparation "Panagen" in Patients With Breast Cancer

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The goal of this trial is to assess the safety, therapeutic dose, and leukostimulatory activity of the preparation Panagen in the therapeutic schemes for treating cancer diseases in the patients receiving a standard chemotherapy for breast cancer of stages II-IV (with distant metastases).
Phase:
Phase 2
Details
Lead Sponsor:
Panagen, Limited Liability Company